ArticleFrontiers in oncology2012
Expression of E-selectin ligands on circulating tumor cells: cross-regulation with cancer stem cell regulatory pathways?
Article in Frontiers in oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 46 citations in OpenAlex.
- Silencing CD24 Inhibits Proliferation, Migration, and Chemoresistance in Triple-Negative Breast Cancer Cells.Pharmaceutical research · 2026Article
- Dual implication of endothelial adhesion molecules in tumor progression and cancer immunity.Cell adhesion & migration · 2025Review
- Oxidative Stress and Inflammation: Drivers of Tumorigenesis and Therapeutic Opportunities.Antioxidants (Basel, Switzerland) · 2025Review
- Targeting inflammation as cancer therapy.Journal of hematology & oncology · 2024Review
- Fucosylation in Urological Cancers.International journal of molecular sciences · 2021Review
- Stem Cell Mimicking Nanoencapsulation for Targeting Arthritis.International journal of nanomedicine · 2021Review
- Biomimetic Microfluidic Platforms for the Assessment of Breast Cancer Metastasis.Frontiers in bioengineering and biotechnology · 2021Review
- Insights into the role of sialylation in cancer progression and metastasis.British journal of cancer · 2021Review
- Serum IL-23, E-selectin and sICAM levels in non-small cell lung cancer patients before and after radiotherapy.The Journal of international medical research · 2020Observational
- High FUT3 expression is a marker of lower overall survival of breast cancer patients.Glycoconjugate journal · 2020Article
- Don't sugarcoat it: How glycocalyx composition influences cancer progression.The Journal of cell biology · 2020Review
- The Role of Proteoglycans in Cancer Metastasis and Circulating Tumor Cell Analysis.Frontiers in cell and developmental biology · 2020Review
- Carcinoembryonic antigen is a sialyl Lewis x/a carrier and an E‑selectin ligand in non‑small cell lung cancer.International journal of oncology · 2019Article
- Dendrimer-Based Platform for Effective Capture of Tumor Cells after TGFβAnalytical chemistry · 2019Article
- The challenge of determining the impact of FUT3 tumor-associated polymorphism rs2306969 (-6951 C> T) in invasive breast cancer cells.Molecular biology reports · 2019Article
- Protein Glycosylation and Tumor Microenvironment Alterations Driving Cancer Hallmarks.Frontiers in oncology · 2019Review
- Conversion of epithelial-to-mesenchymal transition to mesenchymal-to-epithelial transition is mediated by oxygen concentration in pancreatic cancer cells.Oncology letters · 2018Article
- Galectin-1 Influences Breast Cancer Cell Adhesion to E-selectinCellular and molecular bioengineering · 2018Article
- High expression of FUT3 is linked to poor prognosis in clear cell renal cell carcinoma.Oncotarget · 2017Article
- Viscoelasticity Measurements Reveal Rheological Differences Between Stem-like and Non-stem-like Breast Cancer Cells.Cellular and molecular bioengineering · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Although significant progress has been made in the fight against cancer, successful treatment strategies have yet to be developed to combat those tumors that have metastasized to distant organs. Poor characterization of the molecular mechanisms of cancer spread is a major impediment to designing predictive diagnostics and effective clinical interventions against late stage disease. In hematogenous metastasis, it is widely suspected that circulating tumor cells (CTCs) express specific adhesion molecules that actively initiate contact with the vascular endothelium lining the vessel walls of the target organ. This "tethering" is mediated by ligands expressed by CTCs that bind to E-selectin expressed by endothelial cells. However, it is currently unknown whether expression of functional E-selectin ligands on CTCs is related to cancer stem cell regulatory or maintenance pathways, particularly epithelial-to-mesenchymal transition and the reverse, mesenchymal-to-epithelial transition. In this hypothesis and theory article, we explore the potential roles of these mechanisms on the dynamic regulation of selectin ligands mediating CTC trafficking during metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.